| 标题 |
Safety, tolerability, and efficacy of RIPK1 inhibitor, SAR443820, in amyotrophic lateral sclerosis (HIMALAYA): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial |
| 网址 | |
| DOI | |
| 其它 |
期刊:Lancet Neurol 作者:Cudkowicz ME, Shefner J, van den Berg LH, Chio A, Fan D, Großkreutz J, Lunetta C, Tsai RM, Li Y, Wallstroem E, Xiong L, Chen Y, Atassi N, HIMALAYA Phase 2 Study Group 出版日期:2026-10-01 |
| 求助人 | |
| 下载 | 暂无链接,等待应助者上传 |
PDF的下载单位、IP信息已删除
(2025-6-4)